Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards

By S. Vasikaran, Richard Eastell, O. Bruyère, A. Foldes, P. Garnero, A. Griesmacher, M. McClung, H. Morris, S. Silverman, T. Trenti and 3 more. Osteoporosis International, 2011

1,126 citations recorded by the source corpus.

Subfields: Molecular Biology, Nephrology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/c1e175241f603fae885eed2305289b0953ca6953

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Kanis
2. Chris Cooper
3. Eugene V. McCloskey
4. H. Johansson
5. R. Rizzoli
6. J. Reginster
7. on behalf of the International Osteoporosis Foundation
8. Richard Eastell

In Nephrology

1. C. Rosen

In Orthopedics and Sports Medicine

1. Chris Cooper
2. J. Kanis
3. J. Reginster
4. Eugene V. McCloskey
5. R. Rizzoli
6. H. Johansson
7. on behalf of the International Osteoporosis Foundation
8. L. Özışık

Citations in the corpus

• Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. (2019, background): “The BTM response to treatment may account for 30% to 75% of the fracture risk reduction with standard treatments for osteoporosis (163).”
• The clinician’s guide to prevention and treatment of osteoporosis (2022, background): “3–6 months of treatment with specific antiresorptive therapies and increased biochemical markers of formation after 1–3 months of specific anabolic therapies have been predictive of greater BMD responses and (in some cases) fracture risk reduction [93, 293].”
• An overview and management of osteoporosis. (2017, methodology): “International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group evaluated BTMs in the prediction of fracture risk and for monitoring treatment; it was recommended that bone formation markers (s-PINP) and bone resorption mark”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2008, background): “More research is required using standardised analytes before robust evidence-based recommendations can be given [74].”
• European guidance for the diagnosis and management of osteoporosis in postmenopausal women (2018, background): “More research is required using standardised analytes before robust evidence-based recommendations can be given [73].”